ARGs Prevalence Among Hospitalized COVID-19 Patients with Bacterial Infections and Resistome abundance
The burden of antimicrobial resistance AMR worldwide is substantial and is growing. Many factors play a role in the emergence of resistance. Our microbiome is a significant reservoir for antimicrobial resistance genes (ARGs). The use and misuse of antimicrobials can select multi-resistant bacteria and modify the repertoire of ARGs in the gut microbiota. There is clear evidence that hospitalized COVID patients have altered gut microbiota that might affect the prevalence and abundance of AMR. The World Health Organization (WHO) has reported 364 million cases worldwide. Moreover, the CDC announced 72 million positives with more than 4.2 million hospitalized cases in the US alone.
The purpose of the current study is to review AMGs prevalence among hospitalized COVID-19 patients with bacterial infections and explore the alteration of resistome abundance.
We are anticipating that there will be a significant change take place in the gut microbiome, hence the ARGs and resistome abundance in patients with COVID-19.
Display your AMR Technology, Product and Service
Suppliers and Users of Technologies, Products and Services benefit from CAPI.
CAPI (Continuous AMR Partnering Initiative) unites Suppliers and Users worldwide with the aim to add to the curbing of AMR.